PART I Overview We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma and we continue to consider additional indications in mast cell driven diseases for potential future development. We have also historically explored development programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as stem cell trans...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001213900-26-036426 | EDGAR | 99K words |
| 2025-02-28 | 2024-12-31 | 0001213900-25-018384 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001213900-24-020114 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001213900-23-018542 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0001213900-22-013592 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001213900-21-018735 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001213900-20-007505 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001213900-25-107884 | EDGAR | 39K words |
| 2025-08-13 | 2025-06-30 | 0001213900-25-075635 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042011 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001213900-24-095173 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001213900-24-067897 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042805 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001213900-23-084970 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001213900-23-066234 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001213900-23-039021 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071165 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001213900-22-047382 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001213900-22-025945 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-03 | 0001213900-26-084687 | EDGAR | — |
| 2026-07-31 | 0001213900-26-083563 | EDGAR | — |
| 2026-07-17 | 0001213900-26-078887 | EDGAR | — |
| 2026-07-16 | 0001213900-26-078781 | EDGAR | — |
| 2026-03-30 | 0001213900-26-036448 | EDGAR | 3K words |
| 2026-01-08 | 0001213900-26-002329 | EDGAR | — |
| 2026-01-07 | 0001213900-26-002185 | EDGAR | — |
| 2025-12-02 | 0001213900-25-116943 | EDGAR | — |
| 2025-11-10 | 0001213900-25-107874 | EDGAR | — |
| 2025-09-19 | 0001213900-25-089584 | EDGAR | — |
130 total filings indexed. 101 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001788028 |
| Ticker | JSPR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.jaspertherapeutics.com |
| Listed | 2021-09-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/JSPR (~200 tokens, structured JSON with cryptographic provenance)